Humacyte posts Q4 net loss of $20.9M; Symvess commercial launch underway after FDA approval

Humacyte, Inc.

Net loss Q4 2024 $20.9M vs $25.1M Q4 2023; full year net loss $148.7M vs $110.8M.
Cash $95.3M at Dec 31, 2024; raised $46.6M net in March 2025 public offering.
FDA approved Symvess Dec 19, 2024 for extremity vascular trauma; first commercial shipments to two Level 1 trauma centers in Feb 2025.
34 hospitals started VAC approval process; 3 approved; first sales recorded.
R&D expenses $88.6M in 2024 (up 16% YoY); no revenue in period.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.